PHASE Scientific Secures Exclusive U.S. Distribution Rights for FebriDx Rapid Respiratory Infection Test
Key Insights
PHASE Scientific (search) has entered into an exclusive U.S. distribution agreement with Lumos Diagnostics (search) for FebriDx (search), a first-in-class rapid test that differentiates bacterial from non-bacterial respiratory infections (search) in 10 minutes using a single drop of blood.
The FDA 510(k)-cleared test uses C-reactive protein (search) and Myxovirus resistance protein A (search) biomarkers to aid clinical decision-making and antimicrobial stewardship, with a CLIA waiver application expected within three months.
FebriDx (search) will join PHASE Scientific (search)'s INDICAID (search) portfolio, leveraging the company's nationwide clinical network that has distributed over 100 million tests across urgent care centers and healthcare providers.
PHASE Scientific (search) announced it has secured exclusive U.S. distribution rights for FebriDx (search), a rapid point-of-care test that differentiates bacterial from non-bacterial respiratory infections (search) in approximately 10 minutes using a single drop of blood. The partnership with Lumos Diagnostics (search) marks a significant expansion of PHASE's INDICAID (search) respiratory diagnostics portfolio and strengthens its position in the U.S. market.
Revolutionary Diagnostic Technology
FebriDx (search) represents a first-in-class diagnostic solution that addresses critical unmet needs in respiratory infection management. The test utilizes a unique combination of C-reactive protein (search) (CRP) and Myxovirus resistance protein A (search) (MxA) biomarkers to aid clinicians in distinguishing bacterial from non-bacterial acute respiratory infections (search) through a simple fingerstick blood sample.
The lateral flow format test has been validated in pivotal clinical studies and demonstrated good diagnostic performance that can improve diagnostic confidence and antibiotic stewardship decisions. With FDA 510(k) clearance already secured, FebriDx (search) is positioned to transform how clinicians diagnose and manage respiratory infections (search) in point-of-care settings.
"A powerful complement to our INDICAID (search) respiratory portfolio, FebriDx (search) is a first-in-class diagnostic that perfectly aligns with our mission to bring fast, actionable diagnostics to the frontlines of care," said Dr. Ricky Chiu, Founder and CEO of PHASE Scientific (search). "We are confident this will unlock synergistic opportunities, further advancing our impact on antimicrobial stewardship and clinical decision-making across the U.S."
Addressing Antimicrobial Resistance
The diagnostic plays a critical role in addressing the global threat of antimicrobial resistance (search) (AMR), which continues to strain public health systems and drive avoidable costs. By providing rapid, actionable results at the point of care, FebriDx (search) helps reduce unnecessary antibiotic prescribing—a key contributor to AMR—and improves clinical workflows by supporting more accurate triage and treatment.
Clinical studies have demonstrated that integrating FebriDx (search) can lead to reduced antibiotic use, lower healthcare costs, and better patient outcomes. The test's unique ability to guide appropriate prescribing makes it a valuable tool in everyday patient care, particularly in urgent and emergency care settings where rapid decision-making is crucial.
Market Expansion and Commercial Strategy
A CLIA waiver study is progressing well, with anticipated study completion and application submission expected within the next three months. This regulatory milestone would expand access to FebriDx (search) across a broader range of outpatient environments, representing a market opportunity of approximately $1.5 billion.
Doug Ward, CEO of Lumos Diagnostics (search), commented, "This distribution agreement reflects a pivotal moment in Lumos' evolution. We look forward to working with the PHASE Scientific (search) team to ensure that FebriDx (search) secures adoption in the U.S. market, delivering tangible clinical and financial value to the broader healthcare system."
The partnership leverages PHASE Scientific (search)'s proven commercial execution capabilities, including a nationwide network of urgent care centers, clinics, and healthcare providers, along with a track record of distributing over 100 million INDICAID (search) tests. This established infrastructure positions the company to rapidly scale FebriDx (search) adoption across the United States.
Strategic Positioning
This agreement represents a major step in PHASE Scientific (search)'s strategy to reinforce its dual strengths in R&D innovation and commercial execution while accelerating its leadership in the U.S. diagnostics market. Known for its proprietary PHASIFY technology and innovation pipeline in cancer and infectious disease diagnostics, PHASE Scientific is demonstrating its scalable go-to-market strength in North America.
The company recently completed a $34 million Series A funding round, representing the largest Series A raise in Asia's diagnostic technology sector since 2019, with support from the Gates Foundation and U.S. governmental agencies including the National Science Foundation and National Institutes of Health.